BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19935122)

  • 1. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
    Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
    Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
    Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
    J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
    Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
    Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
    Bremond-Gignac D; Nezzar H; Bianchi PE; Messaoud R; Lazreg S; Voinea L; Speeg-Schatz C; Hartani D; Kaercher T; Kocyla-Karczmarewicz B; Murta J; Delval L; Renault D; Chiambaretta F;
    Br J Ophthalmol; 2014 Jun; 98(6):739-45. PubMed ID: 24526744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
    Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
    Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
    Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
    Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
    Ambroziak AM; Szaflik JP; Hapunik A
    Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
    Jackson WB; Low DE; Dattani D; Whitsitt PF; Leeder RG; MacDougall R
    Can J Ophthalmol; 2002 Jun; 37(4):228-37; discussion 237. PubMed ID: 12095096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
    Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
    Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
    Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
    Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis.
    Luchs J
    Adv Ther; 2008 Sep; 25(9):858-70. PubMed ID: 18781287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
    Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
    Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial.
    Cochereau I; Goldschmidt P; Goepogui A; Afghani T; Delval L; Pouliquen P; Bourcier T; Robert PY
    Br J Ophthalmol; 2007 May; 91(5):667-72. PubMed ID: 17005549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
    Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
    Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of azithromycin and tobramycin eye drops on epithelial wound healing and tolerance after penetrating keratoplasty.
    Blavin J; Sauer A; Saleh M; Gaucher D; Speeg-Schatz C; Bourcier T
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):428-32. PubMed ID: 22420841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.